ARTICLE | Company News
Corixa, Rhein deal
April 15, 2002 7:00 AM UTC
RBO obtained co-exclusive marketing rights to CRXA's RC-529 synthetic adjuvant for use with its prophylactic two-dose hepatitis B vaccine and therapeutic hepatitis B vaccine. CRXA, which will supply...